Examining Non-Alcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) among patients diagnosed with Inflammatory Bowel Disease (IBD). It aims to understand the relationship between gut health and liver conditions, particularly focusing on the gut-liver axis. Participants will undergo transient elastometry to assess liver stiffness and steatosis levels. The study seeks to gather data that could illuminate the connection between IBD and liver health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of IBD based on clinical, endoscopic, and histological gounds according to the latest ECCO guidelines
* Willingness to provide informed consent for study participation

Exclusion Criteria:

* Presence of established liver disease (including autoimmune hepatitis, primary biliary cholangitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, positive serology for viral hepatitis B or C)
* History of hepatocellular carcinoma or liver transplantation
* History of excessive alcohol consumption defined as \>3 units per day for women and \> 5 units per day for men
* Pregnancy at the time of recruitment
* Failure to perform an elastography mesure or missing elastography data

Where it's running

• CHU Saint Pierre
  Brussels, Belgium Recruiting

Study contacts

• Study coordinator: Jennifer Aoun, Medical Doctor
• Email: jennifer.aoun@stpierre-bru.be
• Phone: +3225353296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A registry for studying Non-Alcoholic Fatty Liver Disease in Europe

  This study is collecting health information and samples from people with Non-Alcoholic Fatty Liver Disease to learn more about the disease and find better ways to track its progress.

  Recruiting at 33 sites Newcastle University · Antwerp and 36 other locations · NCT04442334

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• Intestinal ultrasound-guided management for inflammatory bowel disease

  This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.

  Recruiting Mahidol University · Bangkok · NCT07775352

• Resting energy use in kids with inflammatory bowel disease

  This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.

  Recruiting Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria · Alessandria, Piedmont · NCT07670975

• Active video education by disease subtype to improve bowel prep before colonoscopy

  We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.

  Recruiting at 12 sites Xijing Hospital of Digestive Diseases · Beijing, BeijingBeijing and 11 other locations · NCT07582731

• Intestinal ultrasound to predict relapse in Crohn's disease patients in deep remission.

  This project will try to see if a noninvasive transabdominal ultrasound can predict relapses in adults with Crohn's disease who are currently in deep remission.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07539727

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.